Puma Biotechnology Inc. buy barry
Summary
This prediction ended on 13.03.22 with a price of €2.40. The BUY prediction by barry for Puma Biotechnology Inc. performed very badly with a performance of -75.14%. barry has 50% into this predictionPuma Biotechnology is a publicly traded biopharmaceutical company that develops innovative cancer therapies targeting the most aggressive and difficult-to-treat forms of the disease. Puma's lead product is Nerlynx, an oral medication approved for the treatment of HER2-positive breast cancer, and the company also has a number of other promising drugs in its pipeline. Founded in 2010, Puma is headquartered in Los Angeles, California, and its shares trade on the NASDAQ exchange under the ticker symbol PBYI.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Puma Biotechnology Inc. | 4.718% | 4.718% | -21.252% | -61.666% |
iShares Core DAX® | 1.510% | 2.268% | 18.541% | 18.577% |
iShares Nasdaq 100 | -0.271% | -1.533% | 22.755% | 34.901% |
iShares Nikkei 225® | -0.108% | 0.411% | 10.352% | -0.876% |
iShares S&P 500 | 0.479% | 0.563% | 22.881% | 38.847% |
Comments by barry for this prediction
In the thread Puma Biotechnology Inc. diskutieren